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Summary 
Background. Bullous pemphigoid (BP) is an autoimmune inflammatory disease causing 
blister formation at the dermo-epidermal junction. Cutaneous infiltration of activated 
CD4+ T cells and eosinophils is an early event in blister formation during the disease 
process, suggesting that the trafficking of circulating leukocytes through the sites of 
inflammation is crucial in the pathogenesis of the disease. While the accumulated 
evidence suggests that some cytokines are involved in the pathogenesis, there have been 
few reports about serum chemokine profile in BP patients.  
Objective. To determine serum profiles of various chemokine levels and clinical 
association in BP patients. 
Methods. Concentrations of 10 chemokines including IP-10, MIG, MIP-1α, MIP-1β, 
RANTES, eotaxin, MCP-1, MCP-2, MCP-3, and GRO-α were measured in serum 
samples from 38 patients with BP, 16 with pemphigus vulgaris (PV), and 17 normal 
controls using a sandwich immunoassay-based multiplex protein array system.  
Results. While there was no significant increase in any serum chemokine levels in PV 
patients, serum levels of IP-10 and MCP-1 were significantly increased in BP patients 
compared with healthy controls. Furthermore, serum levels of IP-10, MIG, MCP-1, and 
eotaxin in BP patients significantly increased with disease severity determined by the 
affected area.
Conclusion. These observations suggest that elaborately orchestrated network of 
chemokines, especially MCP-1 and IP-10, contributes to the pathomechanism of BP. 
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Introduction 
 Bullous pemphigoid (BP) is an autoimmune subepidermal blistering disease, 
usually occurring in the elderly, which is characterized by large, tense blisters. The 
production of autoantibodies directed to a 180-kDa hemidesmosomal protein (BP180) 
of the basement membrane zone is the initiating event of the pathomechanisms1. Once 
the autoantibodies bind to the basement membrane, a cascade of inflammatory events 
occurs, resulting in a subsequent blister formation at the dermo-epidermal junction. 
During this process, cytokines and chemokines are considered to play crucial roles in 
inflammatory cell recruitment, deposition, and perpetuation2. Therefore, clarifying the 
serum and local levels of cytokines and chemokines may help to understand the immune 
dysregulation in the pathomechanism. 
 It has been demonstrated that various cytokines including interleukin (IL)-1β, 
IL-2, IL-4, IL-5, IL-6, IL-8, interferon (IFN)-γ, and tumour necrosis factor 
(TNF)-α increased in sera of BP patients3-8. By contrast, while serum levels of several 
chemokines including eotaxin9-11, “regulated upon activation, normal T-cell expressed 
and presumably secreted” (RANTES)6, thymus and activation-regulated chemokine 
(TARC)12, and mucosae-associated epithelial chemokine (MEC)13 have been reported, 
the involvement of most chemokines in the disease remains unknown. In this study, we 
utilized a recently developed protein array system and assessed the serum levels of 10 
chemokines: IFN-γ-inducible protein-10 (IP-10), monokine induced by IFN-γ (MIG), 
macrophage inflammatory protein (MIP)-1α, MIP-1β, monocyte chemoattractant 
protein (MCP)-1, MCP-2, MCP-3, and growth-regulated oncogene-α (GRO-α), in 
addition to eotaxin and RANTES.  
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Materials and methods 
Subjects.  
 Serum samples obtained from 38 patients with bullous pemphigoid (BP; 17 
females and 21 males; mean age, 71.0 years), 16 patients with pemphigus vulgaris (PV; 
9 females and 7 males; mean age, 55.7 years) and 17 healthy individuals (8 females and 
9 males; mean age, 61.7 years) were examined. BP and PV were diagnosed on the basis 
of clinical features, findings of skin biopsy examinations by light microscopy, direct 
immunofluorescence and indirect immunofluorescence test. Patients with BP and PV 
had not been treated with oral corticosteroids, minocycline/tetracycline, or 
immunosuppressive drugs. As an index of disease severity, the percentage of the body 
surface area covered with skin lesions (oedema, erythema, blisters, erosions) was 
estimated when the serum samples were obtained. Patients affected less than 20%, 
20-40%, and more than 40% of their whole body surfaces were classified into be group 
1 (mild), 2 (intermediate), and 3 (severe), respectively. Institutional review board 
approval and informed consent from all patients and controls were obtained. The 
samples collected were stored at -80° C until use.  
 
Multiplex chemokine assay.  
Ten chemokines simultaneously measured included IP-10, MIG, MIP-1α, 
MIP-1β, RANTES, eotaxin, MCP-1, MCP-2, MCP-3 and GRO-α. A sandwich 
immunoassay-based protein array system (Biosource, Camarillo, CA, USA), which 
contains dyed microspheres conjugated with a monoclonal antibody specific for a target 
protein, was used. Serum samples were thawed and run in duplicates. Antibody-coupled 
beads were incubated with the plasma sample after which they were incubated with 
biotinylated detection antibody before finally being incubated with 
streptavidin-conjugated phycoerythrin. A broad sensitivity range of standards 
(Biosource) ranging from 1.95 to 32,000 pg/ml were used for the quantitation of a 
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dynamic wide range of chemokine concentrations and provide the greatest sensitivity. 
Standards included all the chemokines assayed. This captured immunoassay was then 
read by the Bio-plex array reader (Bio-Rad Laboratories, Hercules, CA, USA) which 
uses Luminex fluorescent-bead-based technology (Luminex Corporation, Austin, TX, 
USA) with a flow-based dual laser detector with real-time digital signal processing to 
facilitate the analysis of up to 100 different families of colour-coded polystyrene beads 
and allow multiple measurements of the sample ensuing in the effective quantitation of 
chemokines. The concentrations of analysis in these assays were quantitated using a 
calibration or standard curve. A regression analysis was performed to derive an equation 
that was then used to predict the concentration of the unknown samples. 
 
Statistical analysis. 
Statistical differences between measured values of BP patients, those of PV 
patients, and those of controls were analyzed using Steel-Dwass’ multiple comparison 
test. Trends in the measured values according to the affected area (disease severity) 
were analyzed by the two-sided Jonckheere-Terpstra test. Correlations between each 
serum chemokine level were analyzed using with Spearman’s correlation coefficient by 
rank test. P values less than 0.05 were considered statistically significant. 
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Results 
Serum levels of ten chemokines in BP and PV patients 
Concentrations of ten chemokines, IP-10, MIG, MIP-1α, MIP-1β, RANTES, 
eotaxin, MCP-1, MCP-2, MCP-3  and GRO-α were simultaneously measured in the 
sera from BP patients, PV patients, and healthy controls. Serum levels of IP-10 and 
MCP-1 were significantly increased in BP patients compared with healthy controls (p = 
0.011 for IP-10 and p = 0.014 for MCP-1, Fig. 1). Serum levels of MIG, MIP-1α, 
MIP-1β, and eotaxin were also slightly higher in BP patients than in controls, although 
the differences were not significant. By contrast, all chemokines except for eotaxin 
showed comparable levels between PV patients and healthy controls (Fig. 1). Serum 
eotaxin levels in PV patients were higher than those in controls although the difference 
was not significant (Fig. 1).  
When each chemokine level higher than the mean + 2SD of the control serum 
samples were considered to be elevated, IP-10 level was elevated in 39%, MIG in 29%, 
MIP-1α in 18%, MIP-1β in 29%, eotaxin in 32% and MCP-1 in 36% of BP patients 
(Table 1). In PV patients, 36% had elevated eotaxin level, 24% had elevated MCP-1 
level, and 18% had elevated IP-10 level. While increased RANTES level was observed 
in one control sample, all the other chemokine levels in control samples were less than 
the mean + 2SD levels. Collectively, BP patients showed more prominent abnormalities 
in chemokine levels than PV patients. 
 
Positive correlation between serum levels of MIG and MCP-1 and the severity. 
To assess the association of chemokine levels with disease severity, BP patients 
were classified into three groups by their affected % areas of the body surface. Group 1 
(mild) included patients affected less than 20% of their whole body surface. Patients 
affected 20-40% and more than 40% of their whole body surfaces were classified into 
group 2 (intermediate) and 3 (severe), respectively. Significant disease severity-related 
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increases in serum levels of IP-10, MIG, MCP-1, and eotaxin (p = 0.008 for IP-10, p = 
0.0007 for MIG, p <0.0001 for MCP-1 and p = 0.005 for eotaxin by Jonckheere-Terpstra 
test) were present (Fig. 2). By contrast, serum levels of MIP-1α, MIP-1β, MCP-2, 
MCP-3, GRO-α, or RANTES showed no such tendency (data not shown). Thus, serum 
levels of MIG, IP-10, MCP-1, and eotaxin appear to reflect the disease severity. 
 
Correlation between serum chemokine levels 
We further analyzed the correlation between serum levels of measured 
chemokines. Serum IP-10 levels in BP patients correlated positively with serum levels 
of MIG (r = 0.385; p =0.018), MCP-1 (r = 0.328; p =0.041), and eotaxin (r = 0.345; p 
=0.031). Serum eotaxin levels also correlated positively with serum concentration of 
MCP-1 (r = 0.490; p = 0.001). There was a strongly positive correlation between serum 
levels of MIP-1α and MIP-1β (r = 0.979, p < 0.0001). Thus, several chemokines were 
concomitantly elevated, which suggests that these cooperatively contribute to the 
disease development. 
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Discussion 
 The aim of this study was to determine the profile of various chemokines 
(IP-10, MIG, MIP-1α, MIP-1β, RANTES, eotaxin, MCP-1, MCP2, MCP-3 and 
GRO-α) in sera from patients with BP. While no chemokine elevated significantly in 
sera from PV patients, BP patients exhibited significantly increased serum levels of 
IP-10 and MCP-1 compared with healthy controls. Serum levels of IP-10, MIG, MCP-1 
and eotaxin in BP patients also showed significant increase with disease severity 
determined by their affected area. Additionally, there were positive correlations between 
IP-10 and MIG, IP-10 and eotaxin, IP-10 and MCP-1, eotaxin and MCP-1, and MIP-1α 
and MIP-1β. Collectively, a variety of chemokines are likely to contribute to the 
development of BP cooperatively. 
Pathogenesis of the inflammatory skin disease is often related to the T helper 
(Th) 1/Th2 balance. BP is considered to be dominantly mediated by Th2 responses. 
Consistently, Kakinuma et al. have reported that serum levels of TARC, a major Th2 
chemokine, were elevated in patients with BP12. While there has been no literature 
describing Th1 chemokines of BP sera, IP-10 and MIG measured in this study are 
considered as chemoattractant of Th1 lymphocytes14. Serum IP-10 levels were 
significantly elevated in whole BP patients compared with controls. Also, there was a 
trend for MIG levels in sera from BP patients to increase in association with the affected 
area. By contrast, serum levels of MIP-1α or MIP-1β, which are also known as Th1 
chemokines15,16, showed neither significant differences between BP patients and 
controls nor trends to increase as the disease severity. Positive correlations between 
IP-10 and MIG levels suggest that IP-10 and MIG may work at adjacent parts of 
intricate inflammatory cascades in the development of BP. Also, considering that 
increase of serum MIG levels were limited in severe patients, MIG may especially 
contribute to exacerbation of BP. Alternatively, insufficient sensitivity of MIG detection 
in this system may interfere with significant differences between serum levels of whole 
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BP patients and controls. Nonetheless, serum IP-10 and MIG levels may also serve as 
indicators for disease severity in BP.  
Interestingly, T cells positive for CXC chemokine receptor 3, which are 
preferentially expressed on Th1-type cells, have been demonstrated to exist beneath the 
bullae17. Furthermore, Budinger et al. have described that the autoreactive T cells, 
which participate in the blister formation of BP and recognize the extracellular domains 
of BP180, possess both Th2 and Th1 cytokines18. Taken together, not only Th2 cells but 
also Th1 cells may be important for pathogenesis of BP. 
BP lesions exhibit prominent eosinophil infiltration. Eotaxin is considered to be 
a potent chemoattractant and activator of eosinophils 19, and main attractant of Th2 
lymphocytes20,21. Although serum eotaxin levels were not significantly increased in total 
BP patients, serum eotaxin levels were associated with disease severity and also 
positively correlated with IP-10 and MCP-1. Correlation between eotaxin and these 
chemokines implies that there may be a similar process for infiltrations of eosinophils 
and another subset of leukocytes including Th1 lymphocytes. Some previous reports 
have demonstrated elevated levels of eotaxin in sera and blister fluid as well as 
increased expression in the skin lesion of BP patients9-11. The enhanced expression of 
eotaxin indicates that this chemokine may also play an important role in the 
pathomechanism of this autoimmune bullous skin disease by recruiting and activating 
eosinophils and lymphocytes. 
MCP-1 is a chemoattractant and activator of monocytes, lymphocytes, and 
basophils, but lacks activity on neutrophils and eosinophils 22,23. Serum MCP-1 levels in 
BP patients were elevated, exhibiting a tendency to increase according to the disease 
severity. Furthermore, MCP-1 levels were correlated positively with IP-10 and eotaxin, 
which act on other types of inflammatory cells than MCP-1 regulates. Therefore, 
correlation between MCP-1 and these chemokines suggests that there may be a similar 
process for infiltrations of different subsets of leukocytes utilizing a variety of 
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chemokines. While there is no literature regarding serum MCP-1 levels in BP, some 
studies have demonstrated that expression of CCR2, the chemokine receptor to which 
MCP-1 binds, increased in chronically inflamed skin lesions of both atopic dermatitis 
and psoriasis24. Therefore, MCP-1 may play an essential role in prolonged inflammation 
of BP lesion. 
Serum RANTES levels did not show significant differences between BP 
patients and controls. RANTES is known as a chemoattractant for monocytes, T 
lymphocytes, and eosinophils25. Our data is consistent with the findings that D’Auria et 
al6. have reported. Furthermore, they demonstrated that the RANTES concentrations in 
blister fluid were less than 1/100 of those in the sera. Therefore, RANTES may be 
rapidly degraded in the blister fluid. Alternatively, RANTES derived from platelets may 
increase the serum concentration.
In summary, the current study indicates that BP patients have a complex 
disorder of various chemokine levels in their sera. This supports that various immune 
pathways are involved in the pathogenesis of BP. It was also remarkable that the 
chemokine profile of the sera from BP patients showed heterogeneity, which may 
suggest that the different profile correspond to distinct disease subset or severity, or may 
reflect different stage of the disease. Nonetheless, it appears that especially MCP-1 and 
IP-10, then MIG and eotaxin, play relatively important roles than the other chemokines 
in BP. Further profiling of immune mediators including chemokines will elucidate the 
precise mechanism of the disease development. 
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Figure legends 
Figure 1: Comparison of serum levels of IP-10, MIG, MIP-1α, MIP-1β, RANTES, 
eotaxin, MCP-1, MCP-2, MCP-3 and GRO-α in patients with BP, PV, and normal 
controls (Control). The measured values from individual patients were plotted by dots. 
The boxes and whiskers indicate the median ± (or +) 25% and maximum/minimum 
values in each group. A broken horizontal line indicates the cut-off value (mean + 2SD 
of the control samples). *p < 0.05 by Steel-Dwass’ multiple comparison test. Significant 
differences were also confirmed using Mann-Whitney U-test with Bonferroni 
correction.
 
Figure 2: Serum levels of IP-10, MIG, MCP-1, and eotaxin in BP patients classified by 
affected area and in controls. Patients affected less than 20%, 20-40%, and more than 
40% of their body surface were classified into Groups 1 (mild), 2 (intermediate), and 3 
(severe), respectively. The boxes and whiskers indicate the median ± (or +) 25% and 
maximum/minimum values in each group.
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Table 1. Frequency of elevated samples of each chemokine.  
  IP-10 MIG MIP-1α MIP-1β Eotaxin MCP-1 MCP-2 MCP-3 RANTES GRO-α 
BP (n = 38) 15 (39) 11 (29) 7 (18) 11 (29) 12 (32) 13 (36) 1 (3) 2 (6) 3 (8) 9 (24) 
PV (n = 17) 3 (18) 3 (18) 1 (6) 1 (6)  6 (36) 4 (24) 1 (6) 0 (0) 1 (6) 3 (18) 
Control (n = 17) 0 (0) 0 (0) 0 (0) 0 (0)  0 (0) 0 (0)  0 (0) 0 (0) 1 (6) 0 (0) 
Values are numbers (percentages) of the patients who showed elevated serum levels of each chemokine (> mean + 2SD of controls).  
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